Sanuwave Health (NASDAQ:SNWV) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Sanuwave Health (NASDAQ:SNWV) announced its quarterly earnings data on Thursday. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.05), FiscalAI reports. The firm had revenue of $9.74 million for the quarter, compared to the consensus estimate of $11.50 million. Sanuwave Health had a net margin of 32.38% and a return on equity of 8,163.31%.

Sanuwave Health Trading Down 2.0%

SNWV traded down $0.12 on Friday, hitting $5.88. 406,357 shares of the company were exchanged, compared to its average volume of 277,744. The firm has a fifty day simple moving average of $9.69 and a two-hundred day simple moving average of $17.00. The company has a debt-to-equity ratio of 8.15, a quick ratio of 0.99 and a current ratio of 1.31. Sanuwave Health has a 12 month low of $5.27 and a 12 month high of $46.58. The stock has a market capitalization of $50.57 million, a PE ratio of 24.50 and a beta of 1.48.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SNWV. Legal & General Group Plc purchased a new position in shares of Sanuwave Health in the second quarter valued at about $26,000. BNP Paribas Financial Markets purchased a new stake in shares of Sanuwave Health during the second quarter worth about $46,000. Russell Investments Group Ltd. purchased a new stake in shares of Sanuwave Health during the third quarter worth about $67,000. State of Alaska Department of Revenue bought a new stake in shares of Sanuwave Health in the fourth quarter worth about $96,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Sanuwave Health in the second quarter worth about $102,000. 42.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “hold (c-)” rating on shares of Sanuwave Health in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Sanuwave Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.